Brands

<h2 dir="ltr">What Are AAV Purification &amp; Packaging Kits?</h2>
 Producing high-titer, high-purity recombinant AAV is a prerequisite for reproducible in vitro and in vivo gene delivery experiments. Impure AAV preparations containing cell debris, empty capsids, and residual transfection reagents reduce functional titer, increase immune activation, and compromise experimental reproducibility. Consistent AAV production requires efficient packaging and purification. Select the kit designed for your vector workflow.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" aria-level="1">
AAV Packaging Mix(1-6) for serotype-specific and efficient gene delivery and AAV production&nbsp;
</li>
<li dir="ltr" aria-level="1">
AAV Serotype Blast&trade; Kit for greater viral yield and enhanced AAV production workflows
</li>
<li dir="ltr" aria-level="1">
AAViralEntry&trade; Transduction Enhancer for improved uptake of AAV and better delivery in mammalian cells
</li>
<li dir="ltr" aria-level="1">
AAV Serotype Blast&trade; Kit for reliable viral vector constructs and AAV production
</li>
</ul>
<h2 dir="ltr"> How to Choose AAV Purification &amp; Packaging Kits</h2>
 Helper-Free Packaging Components Helper-free triple-transfection requires the transgene plasmid (gene of interest flanked by AAV2 ITRs), the rep/cap plasmid (supplying Rep replication proteins and the serotype-specific capsid), and a helper plasmid supplying adenoviral helper functions &mdash; confirm all three components are available for your chosen serotype. Purification Method Iodixanol gradient purification separates full and empty capsids by density without ultracentrifugation in some protocols, while precipitation-filtration kits offer a simpler benchtop alternative for labs without gradient centrifugation capability. Empty vs. Full Capsid Ratio Empty AAV capsids (lacking packaged genome) contribute to particle count without functional activity and can increase immune response in vivo &mdash; purification methods that enrich for full capsids improve both potency and safety profile. Serotype-Specific Rep/Cap Plasmids Each AAV serotype requires its corresponding rep/cap plasmid; confirm the packaging kit includes (or is compatible with) the rep/cap plasmid for your target serotype. Scale of Production Kit formats differ for small-scale research production versus larger-scale preparations intended for multiple in vivo cohorts &mdash; match kit scale to your experimental throughput needs. 
<h2 dir="ltr"> Specifications Context</h2>
 Helper-free triple transfection eliminates the need for co-infection with a replication-competent helper adenovirus, improving safety and simplifying production for standard BSL-2 laboratories. Iodixanol gradient and precipitation-filtration purification approaches are designed to produce research-grade rAAV without requiring ultra-centrifuge access, broadening accessibility for labs setting up AAV production for the first time. As with all recombinant AAV work, production requires institutional biosafety committee (IBC) approval at BSL-2 containment in most jurisdictions. Labs producing AAV for the first time should also plan for functional titering after purification by qPCR for genome copies and by transduction assay for infectious titer, since these two measures can differ substantially, and the functional titer is the more relevant figure for planning experimental MOIs. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team</a> at MBP to confirm packaging system compatibility and serotype availability for your application.

Purfication & Packaging Kits

DataSheet

AAV Packaging Protocol

AAV Packaging Mix (Serotype 5)

Unit Quantity

Note

Shipping Condition

AAV Packaging Mix (Serotype 6)

AAV Serotype Blast™ Kit

Vector

AAV Serotype Blast™ Kit, High Titer

<h2 dir="ltr">What Are AAV Control &amp; Reporter Constructs?</h2>
 Establishing reliable experimental controls is critical in AAV research because transduction efficiency varies substantially by serotype, cell type, multiplicity of infection (MOI), and batch-to-batch variation in viral preparation quality. Matched AAV control and reporter constructs provide the reference point for interpreting experimental results.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Promoter-Specific Blank Vectors used for baseline control, utilize neuron-specific hSyn promoters and high-purity plasmids&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Serotype-Matched Blank Viruses for precise tissue-targeting validation. Available pre-packaged in serotypes 1 through 11
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Bioluminescent Reporter Systems for sensitive measurement of viral delivery.&nbsp; And gene expression featuring luciferase and SV40-luc markers
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Fluorescent Control Constructs carry circ-GFP, GFP, and CBh-gcGFP, for real-time transduction tracking.
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Circular RNA Control Plasmids for advanced non-coding RNA research.&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Cloning-Ready Expression Backbones for selected gene insertion and viral packaging workflows using ampicillin-resistant blank vectors
</li>
</ul>
<h2 dir="ltr"> How to Choose AAV Control &amp; Reporter Constructs </h2>
 Serotype and Backbone Matching The control construct should use the same AAV serotype, ITR configuration, and promoter as the experimental construct, ensuring transduction efficiency differences reflect the transgene rather than vector or serotype variation. Fluorescent Reporter Choice GFP and mCherry reporters allow confirmation of transduction by fluorescence microscopy or flow cytometry, with mCherry offering a red-channel option for multiplexed experiments. Luciferase and Dual-Reporter Options Firefly luciferase provides quantitative bioluminescent transduction confirmation; dual reporter systems (e.g., fluorescent + luciferase) allow both visual and quantitative readouts from the same construct. Empty Vector Baseline An empty AAV vector &mdash; same ITRs, serotype, and promoter, no transgene &mdash; establishes the baseline effect of AAV capsid delivery and innate immune activation, independent of the gene of interest. Batch-to-Batch Variation Controls Because AAV preparation quality can vary between batches, including a transduction-efficiency control (e.g., GFP reporter) alongside each new batch of experimental AAV helps confirm comparable functional titer. 
<h2 dir="ltr"> Specifications Context</h2>
 AAV transduction can activate innate immune sensing pathways and, at high vector doses, induce cellular stress responses independently of the transgene. A matched empty vector or reporter control sharing the same serotype and promoter as the experimental construct helps distinguish vector-related effects from genuine transgene-specific phenotypes. Because AAV infectivity can vary between preparations, reporter-based transduction assessments are commonly used to verify functional performance before experimental studies. For in vivo applications, pilot reporter studies can help confirm tissue targeting and delivery efficiency before larger cohorts are committed. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team </a>at MBP today to get high-quality control/reporter vectors for your lab.

Control/Reporter

Lentiviral Vector Amplification Protocol

AAV Infection Guideline

Selection-Drug Killing Curve

Lentivector Packaging Protocol

Lentivirus Infection Protocol

AAV-CAGGS-Blank Control Vector

Quantity

Vector Map

Guarantee

List of Markers

AAV-CAGGS-Blank-CBh-GFP Control Vector

<h2 dir="ltr">What Are AAV DIO/FLEX Vectors?</h2>
 The DIO (Double-floxed Inverted Open reading frame) architecture &mdash; also called FLEX (FLip-EXcision) or Cre-ON &mdash; is the standard approach for restricting AAV transgene expression to defined cell populations in Cre-driver transgenic mouse lines. The transgene ORF is placed in an antisense (inverted) orientation flanked by two pairs of heterotypic loxP recombination sites until Cre recombinase is present.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" role="presentation">DIO CMV Expression Vectors use the CMV promoter for Cre-dependent and highly specific transgene expression.</li>
<li dir="ltr" role="presentation">Selection-Ready DIO Plasmids used for efficient selection of antibiotics in transduced cells, and feature SV40-Puro markers.</li>
<li dir="ltr" role="presentation">Fluorescent Reporter DIO Vectors carry copGFP or GFP for visually verifying recombination.</li>
<li dir="ltr" role="presentation">Customizable DIO Blank Backbones for insertion of specific genes of interest into a conditional framework.</li>
</ul>
<h2 dir="ltr"> How to Choose an AAV DIO/FLEX Vector</h2>
 Packaging Capacity Constraint AAV DIO vectors are limited to expression cassettes of approximately 4.2 kb due to the ~4.7 kb AAV genome capacity, including the loxP recombination architecture itself &mdash; a key consideration for larger transgenes. Cre-Driver Line Compatibility The vector must be paired with a Cre-driver transgenic mouse line expressing Cre in the cell population of interest, or with co-delivery of a Cre-expressing vector for cell-culture validation. Serotype for Target Region As with standard AAV over-expression, serotype selection determines tissue tropism &mdash; critical for targeting specific brain regions or cell types in neuroscience applications. Permanence of Activation Once Cre flips the ORF into sense orientation and excises one site from each loxP pair, the transgene is permanently locked in the ON orientation &mdash; heritable expression is maintained without continued Cre activity. Validation Strategy Before in vivo injection, co-transfection of the AAV DIO vector with a Cre expression plasmid in HEK293T cells confirms efficient inversion and expected expression; transfecting the DIO vector alone confirms the absence of leaky expression. 
<h2 dir="ltr"> Specifications Context</h2>
&nbsp;
AAV DIO (Double-Floxed Inverted Orientation) vectors are widely used for cell-type-specific conditional gene expression in Cre-driver animal models, supporting applications such as circuit mapping, optogenetics, chemogenetics, and in vivo functional studies. Because transgene expression depends on Cre-mediated recombination, researchers should verify Cre-driver specificity and recombination efficiency in their chosen model before large-scale experiments. Low-level Cre-independent ("leaky") expression can occasionally occur in DIO systems and should be evaluated using appropriate control vectors. The practical packaging capacity of AAV is approximately 4.7 kb, which may limit the size of the transgene cassette that can be accommodated. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team </a>at MBP today and get a quote for premium AAV DIO vector requirements.